Deb-Chatterji, Milani http://orcid.org/0000-0003-4282-3518
Schlemm, Eckhard
Flottmann, Fabian
Meyer, Lukas
Alegiani, Anna
Brekenfeld, Caspar
Fiehler, Jens
Gerloff, Christian
Thomalla, Götz
Gerloff, C.
Fiehler, J.
Thomalla, G.
Alegiani, A.
Boeckh-Behrens,
Wunderlich, Silke
Ernemann, Ulrike
Poli, Sven
Siebert, Eberhard
Nolte, Christian H.
Zweynert, Sarah
Bohner, Georg
Ludolph, Alexander
Henn, Karl-Heinz
Pfeilschifter, Waltraud
Keil, Fee
Röther, Joachim
Eckert, Bernd
Berrouschot, Jörg
Bormann, Albrecht
Solymosi, László
Petzold, Gabor
Kraemer, Christoffer
Dichgans, Martin
Tiedt, Steffen
Kellert, Lars
Dorn, Franziska
Petersen, Martina
Stögbauer, Florian
Braun, Michael
Hamann, Gerhard F.
Gröschel, Klaus
Uphaus, Timo
,
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 10 September 2020
Accepted: 21 November 2020
First Online: 21 December 2020
Compliance with ethical guidelines
:
: M. Deb-Chatterji, E. Schlemm, F. Flottmann, L. Meyer, C. Brekenfeld declare that they have no competing interests. A. Alegiani reports honoraria as speaker from Bayer Vital. J. Fiehler receives research support from the German Ministry of Science and Education (BMBF), German Ministry of Economy and Innovation (BMWi), German Research Foundation (DFG), European Union (EU), Hamburgische Investitions- und Förderbank (IFB), Medtronic, Microvention, Philips, Stryker; and serves as a consultant for Acandis, Boehringer Ingelheim, Cerenovus, Evasc Neurovascular, MD Clinicals, Medtronic, Medina, Microvention, Penumbra, Route92, Stryker, Transverse Medical. C. Gerloff serves on scientific advisory boards for Bayer Vital, Boehringer Ingelheim, Acticor Biotech, Amgen, and Prediction Biosciences; has received funding for travel and/or speaker/consulting honoraria from Bayer Vital, Boehringer Ingelheim, Sanofi Aventis, Amgen, EBS Technologies, GlaxoSmithKline, Lundbeck, Pfizer, Silk Road Medical, and UCB, and Abbott; serves on editorial boards for INFO Neurologie & Psychiatrie and Aktuelle Neurologie and as editor of textbook Therapie und Verlauf neurologischer Erkrankungen; has received grants to supporting employees/scientists of his clinic from Merz Pharmaceuticals, Allergan, Novartis, and NeuroConn; and receives research support from Deutsche Forschungsgesellschaft, the European Union, Wegener Foundation, Schilling Foundation, and Werner-Otto-Foundation. G. Thomalla has received personal fees as consultant or lecturer from Acandis, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daichi Sankyo, Stryker, and research grants from Bayer, Federal Ministry for Economic Affairs and Energy (BMWi), Corona-Foundation, German Research Foundation (DFG), Else Kröner-Fresenius Foundation, European Union (Horizon 2020), German Innovation Fund.
: The study was approved by the responsible ethics committees of all participating sites, and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from the patient or the proxy prior inclusion in the study. Consent was waived if patients died before consent could be obtained or lacked the capacity to give consent and no proxy was available.